The latest price target for Centessa Pharmaceuticals (NASDAQ:CNTA) was reported by Oppenheimer on December 10, 2025. The analyst firm set a price target for $62.00 expecting CNTA to rise to within 12 months (a possible 137.09% upside). 18 analyst firms have reported ratings in the last year.

The latest analyst rating for Centessa Pharmaceuticals (NASDAQ:CNTA) was provided by Oppenheimer, and Centessa Pharmaceuticals maintained their outperform rating.

The last upgrade for Centessa Pharmaceuticals PLC happened on September 19, 2024 when Morgan Stanley raised their price target to $26. Morgan Stanley previously had an equal-weight for Centessa Pharmaceuticals PLC.

There is no last downgrade for Centessa Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Centessa Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Centessa Pharmaceuticals was filed on December 10, 2025 so you should expect the next rating to be made available sometime around December 10, 2026.

While ratings are subjective and will change, the latest Centessa Pharmaceuticals (CNTA) rating was a maintained with a price target of $40.00 to $62.00. The current price Centessa Pharmaceuticals (CNTA) is trading at is $26.15, which is out of the analyst’s predicted range.